Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
1 May 2004
American Academy of Sleep Medicine - Professional Association
Summary,
GUIDELINE OBJECTIVE(S)
To serve as a guide for the appropriate use of dopaminergic agents in the treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD)
TARGET POPULATION
Patients with restless legs syndrome (RLS) and periodic limb movement disorder (PLMD)
INTERVENTIONS AND PRACTICES CONSIDERED
1. Levodopa with decarboxylase inhibitor
2. Pergolide*
3. Pramipexole
4. Ropinirole
5. Other dopamine agonists including talipexole cabergoline, piribedil, and alpha-dihydroergocryptine
6. Amantadine and selegiline
*Note from the National Guideline Clearinghouse (NGC): On March 29, 2007, Permax (pergolide) was withdrawn from the market in the U.S. and worldwide due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information.
MAJOR OUTCOMES CONSIDERED
* Therapeutic efficacy of dopaminergic agents for treatment of RLS and PLMD
* Sleep parameters (total sleep time, sleep efficiency)
* Restless legs syndrome (RLS) and periodic leg movement disorder (PLMD) symptoms
* Adverse effects
* Quality of life
American Academy of Sleep Medicine - Professional Association
Summary,
GUIDELINE OBJECTIVE(S)To serve as a guide for the appropriate use of dopaminergic agents in the treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD)
TARGET POPULATION
Patients with restless legs syndrome (RLS) and periodic limb movement disorder (PLMD)
INTERVENTIONS AND PRACTICES CONSIDERED
1. Levodopa with decarboxylase inhibitor
2. Pergolide*
3. Pramipexole
4. Ropinirole
5. Other dopamine agonists including talipexole cabergoline, piribedil, and alpha-dihydroergocryptine
6. Amantadine and selegiline
*Note from the National Guideline Clearinghouse (NGC): On March 29, 2007, Permax (pergolide) was withdrawn from the market in the U.S. and worldwide due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information.
MAJOR OUTCOMES CONSIDERED
* Therapeutic efficacy of dopaminergic agents for treatment of RLS and PLMD
* Sleep parameters (total sleep time, sleep efficiency)
* Restless legs syndrome (RLS) and periodic leg movement disorder (PLMD) symptoms
* Adverse effects
* Quality of life
